Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR

21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...

Read more →

Quebec becomes first province to cover Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia

6 February 2023 - First and only Bruton's tyrosine kinase inhibitor to be granted provincial formulary approval. ...

Read more →

Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours

1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada. ...

Read more →